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Abstract
Pulmonary hypertension (PH) commonly develops in thalassaemia syndromes, but is poorly 
characterized. The goal of this study was to provide a comprehensive description of the 
cardiopulmonary and biological profile of patients with thalassaemia at risk for PH. A case-control 
study of thalassaemia patients at high versus low PH-risk was performed. A single cross-sectional 
measurement for variables reflecting cardiopulmonary status and biological pathophysiology were 
obtained, including Doppler-echocardiography, 6-minute-walk-test, Borg Dyspnea Score, New 
York Heart Association functional class, cardiac magnetic resonance imaging (MRI), chest-
computerized tomography, pulmonary function testing and laboratory analyses targeting 
mechanism of coagulation, inflammation, haemolysis, adhesion and the arginine-nitric oxide 
pathway. Twenty-seven thalassaemia patients were evaluated, 14 with an elevated tricuspid-
regurgitant-jet-velocity (TRV) ≥2.5m/s. Patients with increased TRV had a higher frequency of 
splenectomy, and significantly larger right atrial size, left atrial volume and left septal-wall 
thickness on echocardiography and/or MRI, with elevated biomarkers of abnormal coagulation, 
lactate dehydrogenase levels and arginase concentration, and lower arginine-bioavailability 
compared to low-risk patients. Arginase concentration correlated significantly to several 
echocardiography/MRI parameters of cardiovascular function in addition to global-arginine-
bioavailability and biomarkers of haemolytic rate, including lactate dehydrogenase, haemoglobin 
and bilirubin. Thalassaemia patients with a TRV ≥2.5m/s have additional echocardiography and 
cardiac-MRI parameters suggestive of right and left-sided cardiac dysfunction. In addition, low 
arginine bioavailability may contribute to cardiopulmonary dysfunction in β-thalassaemia.
Keywords
Arginase; β-thalassaemia; global arginine bioavailability ratio; haemolysis; pulmonary 
hypertension
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Cardiovascular complications are among the leading causes of mortality and morbidity in β-
thalassaemia (Anthi, et al 2013, Farmakis and Aessopos 2011, Morris and Vichinsky 2010). 
It has been postulated that haemoglobinophathies, along with human immunodeficiency 
virus infection and schistosomiasis, may be the most common causes of pulmonary 
hypertension (PH) worldwide (Machado and Farber 2013), given the high prevalence of 
these diseases globally. In particular, PH develops frequently in patients with haemolytic 
anemias (Aessopos, et al 2005, Farmakis and Aessopos 2011, Morris 2008), including β-
thalassaemia. An elevated tricuspid-regurgitant-jet-velocity (TRV) ≥2.5 m/s on Doppler 
echocardiography (echo) is a common finding in patients with thalassaemia (Morris, et al 
2011) and can identify those at increased risk for PH, although a right heart catheterization 
(RHC) is required to confirm a PH diagnosis. In patients with sickle cell disease (SCD), 
another haemolytic anaemia commonly associated with PH, RHC-defined PH is found in 
6-11% of patients and is associated with a high mortality risk (Fonseca, et al 2012, Gladwin 
2011, Mehari, et al 2012, Parent, et al 2011). An elevated TRV does not carry the same 
short-term mortality risk in thalassaemia patients that is observed in SCD (Morris, et al 
2011), however the long-term consequences of PH in β-thalassaemia remain unknown, 
routine screening is not yet common practice, at-risk patients are not well characterized and 
few patients receive PH therapy (Morris and Gladwin 2011, Morris and Vichinsky 2010). 
Pathophysiological changes of PH have been demonstrated postmortem on autopsy studies 
in thalassaemia intermedia (TI) (Sonakul, et al 1988), and a recent multi-centre study using 
RHC to screen β-thalassaemia patients with a TRV ≥3.2 m/s revealed a 2.1% prevalence of 
PH among 1309 Italian thalassaemia patients screened by echocardiography (Derchi, et al 
2014). There was a 5-fold higher prevalence of PH in TI patients compared to thalassaemia 
major (TM) (Derchi, et al 2014), suggesting that the prevalence of PH in TI is similar to that 
of SCD (Gladwin 2011, Parent, et al 2011). However, not all at-risk patients underwent 
RHC and a TRV >3.2 m/s is a conservative cut-off for screening that may underestimate the 
true prevalence, particularly since 31 out of 33 thalassaemia patients (94%) who underwent 
a RHC ultimately had confirmed PH (Derchi, et al 2014). Advanced age, splenectomy, 
transfusion-naivety and an elevated nucleated red blood cell count are associated with PH in 
β-thalassaemia (Derchi, et al 2014, Karimi, et al 2011, Morris, et al 2011, Morris and 
Vichinsky 2010, Singer, et al 2014, Singer, et al 2006). The aetiology of PH is 
multifactorial, and may include the long-term effects of splenectomy, erythrocyte cell 
membrane pathology, coagulation abnormalities/thrombosis, reduced nitric oxide (NO) 
bioavailability, excess arginase activity, platelet activation, oxidative stress, iron overload, 
chronic haemolysis and the anaemia itself (Aessopos, et al 2005, El-Hady, et al 2012, 
Morris 2008, Morris, et al 2013a, Morris, et al 2007, Morris and Vichinsky 2010, Singer, et 
al 2014, Singer, et al 2006). In addition, the process of haemolysis disables the arginine-NO 
pathway through the simultaneous release of erythrocyte-arginase and cell-free 
haemoglobin, where both NO and its obligate substrate arginine are rapidly consumed 
(Morris, et al 2005a, Morris, et al 2005b, Morris, et al 2007, Morris 2008, Reiter, et al 
2002).
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Given the paucity of data available characterizing patients with a thalassaemia syndrome at 
risk for PH, the Thalassemia Clinical Research Network (TCRN) performed a case-control 
study to provide a comprehensive description of the cardiopulmonary and biological profile 
of thalassaemia patients with an elevated TRV (≥2.5 m/s) compared to normal TRV (<2.5 
m/s).
METHODS
Subject Recruitment and Clinical Evaluation
The TCRN is a National Institutes of Health-sponsored network of major thalassaemia 
centres in the US, Canada, UK and Lebanon. All patients were enrolled at participating 
TCRN centres (Beirut, Boston, Chicago, London, Oakland, Philadelphia and Toronto). 
Local institutional review boards approved the protocol and written informed consent was 
obtained from all subjects. Subjects with a thalassaemia syndrome (alpha, beta or E-beta-
thalassaemia), confirmed by haemoglobin electrophoresis or by molecular diagnosis, aged 
≥7 years old with a measurable TRV on Doppler-echocardiography were eligible. Patients 
undergoing chronic transfusion therapy had evaluations within 7-10 days prior to their next 
scheduled transfusion. A patient requiring < 8 transfusions/year was characterized as TI.
Study Design
This is a case-control study of thalassaemia patients at risk for PH, defined by a TRV 
≥2.5m/s on Doppler-echocardiography compared to patients with a thalassaemia syndrome 
at lower risk for PH, defined by a TRV <2.5m/s. A single cross-sectional measurement for 
variables reflecting cardiopulmonary status and biological pathophysiology were obtained, 
including vital signs, a 6-minute-walk-test (6MWT) with assessment of Borg Dyspnea Score 
and New York Heart Association (NYHA) functional class, echo with measurement of TRV 
(m/s), pulmonary function testing including spirometry, lung volumes and gas exchange 
capacity of the lungs by single-breath diffusion capacity for carbon monoxide (DLCO), 
cardiac magnetic resonance imaging (MRI), chest computerized tomography (CT) scans, 
routine laboratory measurements and assays for biomarkers of coagulation, inflammation, 
haemolytic rate, the arginine-NO pathway and adhesion molecules. (See Supplement Table 
1 for list of all biological assays measured).
Doppler Echocardiography
Echocardiography was performed according to the American Society of Echocardiography 
guidelines at the participating institutions and read locally. Eligibility confirmation 
evaluation of TRV on screening echocardiogram was blindly read centrally at the Brigham 
and Women's Hospital Cardiovascular Imaging Core Laboratory (Core Lab). 
Echocardiographers were centrally trained and certified for this protocol. Examinations were 
recorded on separate tapes for each participant and copies sent to the Core Lab for central 
analysis.
See supplemental for detailed methods for the 6MWT, pulmonary function testing, MRI and 
chest CT scans.
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Routine laboratory tests (complete blood count, serum chemistry profile and ferritin) were 
performed in the local laboratories of the participating institutions. The plasma and 
erythrocyte arginine metabolites were analysed via high pressure liquid chromatography-
linked tandem mass spectrometry (LC/MS/MS), as previously described (Morris, et al, 
2008, Morris, et al 2013a). Arginase activity and concentration, biomarkers of haemolysis, 
coagulation, inflammation and adhesion were measured through standard methods by the 
Frans Kuypers laboratory at Children's Hospital Oakland Research Institute (Red Blood Cell 
Laboratory; rbclab.com) and through LabCorp – Esoterix Clinical Trials (Cranford, NJ; 
www.labcorp.com).
Arginase concentration—Arginase concentration was measured using a double 
monoclonal sandwich enzyme-linked immunoassay (ELISA) for the quantitative 
measurement of human liver-type arginase in serum (BioVendor Laboratory Medicine, Inc., 
Chandler, NC) according to the manufacturer's protocol.
Arginase activity—Arginase activity was determined as the conversion of [14C-
guanidino]-L-arginine to [14C]urea, which was converted to 14CO2 by urease and trapped as 
Na2 14CO3 for scintillation counting, as previously described (Morris, et al 2005b, Morris, et 
al 2013a).
Statistical Analysis
Descriptive statistics were reported as the number and percentage, or the mean and standard 
deviation. Differences in categorical variables were tested by Fisher's exact test and 
differences in continuous variables were tested by t-test and analysis of variance (ANOVA). 
Correlation analysis and linear regression were used to test for associations between 
arginase activity/concentration, TRV, laboratory parameters and other covariates of interest. 
Multiple linear regression analysis with stepwise selection was used to evaluate predictors of 
arginase activity/concentration. Variables that were significant in the univariate analysis 
(P<0.05) were included. Log-transformation was used as needed to correct for skew in the 
data. All analyses were performed at the Data Coordinating Center (New England Research 
Institutes, Watertown, MA) with SAS statistical software (9.2, SAS Institute, Cary, NC) and 
R (2.11.1, The R Foundation for Statistical Computing, http://www.r-project.org/). P-
values<0.05 were considered statistically significant.
RESULTS
Subject Characteristics
Twenty-seven patients with a thalassaemia syndrome were included in this study. The cohort 
is notable for a high prevalence of splenectomy, paucity of patients transfused since infancy, 
a relatively high average pre-transfusion haemoglobin and 66.7% of patients with TM. 
Patient demographics and clinical characteristics are summarized in Table I. Patients with a 
history of a high TRV ≥2.5 m/s (n=14) were prospectively recruited and screened by 
echocardiography at participating sites. A control group of thalassaemia patients with a 
normal TRV (<2.5 m/s, n=13) were also recruited for participation. Mean TRV for the TRV 
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≥2.5 m/s group was 3.1±0.7 m/s (range: 2.7-5.3 m/s). Splenectomy was common in patients 
with an elevated TRV ≥2.5m/s (Odds Ratio=11.1 [95% confidence interval [CI]:1.11-112.0], 
p=0.04).
Cardiopulmonary Evaluations
Cardiopulmonary characteristics of patients with thalassaemia according to TRV categories 
(TRV<2.5, TRV=2.5-2.8, TRV≥2.9 m/s respectively) are summarized in Table II. The 
concordance correlation coefficient for baseline TRV measurements (local site interpretation 
compared to Core Lab) was 0.94 (95% CI: 0.90-0.99), which demonstrated an excellent 
agreement between sites. The concordance correlation coefficient measures the agreement 
between measurements, to evaluate reproducibility or for inter-rater reliability. Systolic and 
diastolic blood pressure, heart rate and pulse pressure were similar across TRV categories. 
Patients with an increased TRV had a higher NYHA functional class and Borg Dyspnea 
Score, suggestive of increased dyspnea after the 6MWT compared to normal TRV controls.
Echo measurements of right atrial size (p=0.03), left atrial size (p=0.002), left ventricular 
(LV) mass (p=0.03) and LV septal wall thickness (p=0.03) were significantly larger in 
patients with a TRV≥2.9 and TRV=2.5-2.8 m/s compared to patients with a TRV<2.5 m/s 
and remained significantly different when parameters were indexed to body surface area 
(BSA). MRI measurements of left atrial volume were significantly higher in patients with 
TRV≥2.5 m/s compared to those with a TRV<2.5 m/s (p=0.008). TRV correlated to right 
atrial size (cm2) (r =0.5, p=0.01) by echo, right (r=0.65, p=0.01) and left atrial volume (r 
=0.56, p=0.03) on MRI and creatinine (r =0.42, p=0.03) but not to other cardiopulmonary 
parameters or clinical/laboratory biomarkers. In particular there were no associations of 
TRV with 6-minute walk distance (6MWD, r =0.13, p=0.51), brain natriuretic factor (BNP, 
r =0.01, p=0.99) or biomarkers of haemolytic rate including LDH (r =0.25, p=0.22). 
Although there was no significant difference in 6MWD based on TRV categories, the 
6MWD paradoxically trended higher in patients with a TRV≥2.5m/s. The 6MWD also 
paradoxically correlated to right atrial size (r =0.42, p=0.03), as well as DLCO (r =0.51, 
p=0.008) and DLCO corrected for haemoglobin (r =0.54, p=0.005). DLCO was generally 
low in our cohort of thalassaemia patients (mean % predicted: 68.2±16.3 [range 45-115, 
n=27]), however other measurements of pulmonary function were within the normal range 
and did not differ significantly by TRV. However, 29.6% (8/27) of patients had an forced 
expiratory volume in 1 s (FEV1)% predicted < 80%, but a normal FEV1/forced vital 
capacity (FVC) suggestive of restrictive physiology.
Chest CT scanning of these patients revealed areas of intramedullary haematopoiesis within 
the vertebrae and ribs consistent with thalassaemia. Approximately 1/3-1/2 of patients had 
normal lung parenchyma regardless of TRV. The rest had a combination of ground glass 
infiltrates, mosaic attenuation and/or sub-centimetre pulmonary nodules. The small number 
of patients in each group limited our ability to determine if a different pattern was observed 
with increasing TRV. Interestingly, pulmonary artery size, a non-specific finding in PH, was 
not significantly different between those patients with an elevated TRV compared to those 
with a normal TRV.
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Routine clinical laboratory tests and biomarkers of haemolysis, arginine bioavailability, 
coagulation, inflammation and adhesion were analysed and compared by TRV sub-groups 
(Table III; see Supplemental Table I for list of all analyses). Lactate dehydrogenase (LDH) 
was significantly higher in patients with an elevated TRV compared to those with a 
TRV<2.5m/s (p=0.03), as were biomarkers of abnormal coagulation (thrombin-anti-
thrombin [TAT] complex, p=0.04, and monoclonal prothrombin fragment 1.2 [PF12 mono], 
p=0.02). Plasma arginine concentration and biomarkers of global arginine bioavailability 
(GAB, plasma arginine/ornithine ratio and arginine/(ornithine+citrulline) ratio) were 
significantly lower in patients with a TRV≥2.5 m/s compared to those with a normal TRV, 
while arginase concentration and activity were high (Figure 1).
The relationship between arginase activity/concentration and clinical as well as laboratory 
markers of disease severity were evaluated to identify potential mechanisms for increased 
enzymatic activity and associated effects on organ function (Table IV). As expected, 
arginase activity and concentration strongly correlated to each other (r =0.74, p<0.0001). 
Arginase concentration and activity similarly correlated significantly to several 
echocardiography and cardiac-MRI parameters of cardiovascular function in addition to 
global arginine bioavailability (Table IV, correlations for arginase concentration reported) 
and biomarkers of haemolytic rate, including LDH, haemoglobin and bilirubin. These 
associations were more profound in TI patients (arginase concentration Pearson correlation 
to plasma arginine (r =−0.72, p=0.04), plasma arginine/ornithine ratio (r =−0.82, p=0.01), 
and plasma argininine/(ornithine+cirtrulline) ratio (r −0.79, p=0.02; N=9). No significant 
association of arginase with alanine transaminase argues against hepatic arginase as a major 
source of excess arginase concentration in our cohort of patients with thalassaemia. 
Although arginase concentration correlated with white blood cell count, no other 
associations with biomarkers of coagulation or inflammation were identified. Interestingly, 
arginase activity correlated with several biomarkers of coagulation, including PF12 mono (r 
=0.40, p=0.04), TAT complex (r =0.41, p=0.04) and tissue factor concentration (r =0.45, 
p=0.02). Arginase activity also correlated strongly with BNP (r =0.51, p=0.007), while 
arginase concentration showed no relationship (r =0.17, p=0.42). Of the adhesion markers 
measured, arginase concentration correlated directly with soluble Intercellular Adhesion 
Molecule 1 (r =0.41, p=0.04) and inversely with L-selectin concentration (r =-0.44, p=0.03). 
In multiple regression analysis, variables significantly associated with arginase 
concentration (p<0.05) were considered in a stepwise selection process. Cardiac index, 
bilirubin and plasma arginine/ornithine ratio remained significant in the final model with 
arginase concentration (R2=0.68, p<0.05 for all independent variables).
No significant differences were found in biomarkers of inflammation or adhesion molecules 
across TRV measurements. (See supplemental Table I for specific biomarkers of 
inflammation and adhesion measured).
DISCUSSION
This study provides a comprehensive cardiopulmonary and laboratory profile of patients 
with thalassaemia and an elevated TRV≥2.5 m/s at increased risk for PH compared to 
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patients with a TRV<2.5 m/s, considered at lower risk for PH. Patients with TRV elevation 
had a higher frequency of splenectomy and significantly larger right atrial size, left atrial 
volume and left septal-wall thickness on echocardiography and/or cardiac-MRI, with 
elevated biomarkers of abnormal coagulation, LDH levels and arginase concentration and 
lower GAB compared to the TRV<2.5 m/s group. As expected, NYHA functional class was 
higher in patients with higher TRVs. However no differences in pulmonary function tests or 
chest CT scans were identified in patients at high vs. normal TRV. Chest CT scanning was 
abnormal, however, in over half of the patients evaluated. Pulmonary function tests 
suggested restrictive lung disease in nearly 30% of the thalassaemia cohort, a high 
proportion but less frequent than observed in SCD (Klings, et al 2006).
Most intriguing from the biological studies was the emergence of arginine dysregulation as a 
factor strongly associated with cardiopulmonary dysfunction in this thalassaemia cohort. 
This study demonstrates that low GAB in thalassaemia occurs predominantly in patients 
with an elevated TRV. We have previously reported low GAB in thalassaemia compared to 
normal control subjects (Morris, et al 2005a), however patients were not differentiated by 
TRV or cardiopulmonary dysfunction. Of interest, Meloni et al (2015) recently published an 
association of TRV elevation with reduced GAB, together with increased anaemia, cardiac 
index and diastolic dysfunction in 60 TM patients. We describe, however, the first report to 
identify excess arginase activity as a key mechanism associated with low GAB in 
thalassaemia. Reduced GAB and NO depletion represent a common theme in otherwise 
distinct vasculopathies (Morris 2008) and can result from a number of mechanisms, 
including haemolysis (Morris, et al 2005a, Morris, et al 2005b, Morris, et al 2003, Morris, et 
al 2008). However, low GAB is associated with coronary artery disease and major adverse 
cardiovascular events including mortality in patients screened for cardiovascular disease 
(Tang, et al 2009, Wang, et al 2009), just as it is associated with degree of arginase activity, 
PH-risk and mortality in SCD (Cox, et al 2011, Morris, et al 2005b) and mortality risk in 
malaria (Omodeo-Sale, et al 2010). Hypoxic upregulation of arginase II occurs in human 
lung endothelial cells, while high shear stress has also been found to regulate the arginase 
pathway (Pernow and Jung 2013). These events may also contribute to excess arginase 
activity in some patients. Low GAB may represent a unifying mechanism of cardiovascular 
dysfunction that is not disease-specific. The “GAB ratio” (GABR) is defined as the ratio of 
arginine to (ornithine+citrulline), and accounts for levels of the substrate (arginine) and its 
major catabolic products (ornithine and citrulline) in vivo (Morris, et al 2005b, Tang, et al 
2009). Arginine is the common substrate for both NO-synthases and the arginases. Whether 
inflammatory or haemolytic in origin, arginase will redirect the metabolism of arginine away 
from NO to ornithine and the formation of polyamines and proline, which are essential for 
smooth muscle cell growth and collagen synthesis. By creating a shift towards ornithine 
metabolism, arginase may contribute to a proliferative vasculopathy common to haemolytic 
disorders (Morris, et al 2005a, Morris 2008, Morris 2014, Morris, et al 2005b, Morris, et al 
2013b) but also common to cardiovascular disease (Erdely, et al 2010, Sourij, et al 2011, 
Tang, et al 2009), heart failure (Tang, et al 2013) and PH (Morris and Gladwin 2011). 
GABR is also associated with advanced LV diastolic dysfunction, increased severity of right 
ventricular systolic dysfunction, and poorer long-term adverse clinical outcomes in 
nonhaemolytic patients with chronic systolic heart failure (Tang, et al 2013) and diabetes 
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(Tripolt, et al 2012). Low GAB may be exacerbated further by the presence of asymmetric 
dimethlyarginine (ADMA), an endogenous NO-synthase inhibitor that competes with L-
arginine for binding to NO-synthases. Well established as another biomarker of 
cardiovascular disease and endothelial dysfunction, elevated circulating ADMA levels have 
been implicated in the pathophysiology of systemic and PH and risk of early mortality 
(Wang, et al 2009). In patients with SCD, elevated ADMA levels were found in patients 
with the highest haemolytic rate and were also associated with PH-risk and early death 
(Kato, et al 2009). Similarly, high plasma ADMA levels have recently been implicated in 
the pathogenesis of TRV elevation in children with β-thalassaemia (Mohamed, et al 2014). 
Excess ADMA can also contribute to NO-synthase uncoupling (Morris 2008), which is an 
additional mechanism of arginine dysregulation that impacts GAB. It is interesting to note 
that sildenafil treatment increased GAB in thalassaemia patients with an elevated TRV 
(Morris, et al 2013a), and may represent a novel mechanism of action for this Food and 
Drug Administration-approved PH therapy that warrants further investigation.
It is notable that biomarkers of haemolytic rate, including LDH (Kato, et al 2006) and 
arginase (Morris, et al 2005b), were substantially different across TRV categories, however 
cell-free haemoglobin levels did not differ, and did not correlate strongly to other 
biomarkers of haemolysis including arginase activity/concentration or LDH as it has in other 
cohorts (Hill, et al 2010, Morris, et al 2005b). It is possible that sufficient haptoglobin 
and/or haemopexin were available in some patients to bind and eliminate cell-free 
haemoglobin to some degree, a consideration to evaluate in future studies. It is also possible 
that arginase is endothelial cell-derived rather than from the erythrocyte, in response to shear 
stress from a high cardiac output associated with anaemia. Although multiple sources of 
plasma arginase are most likely, this study could not differentiate between arginase isoforms 
or specific cell-types of origin.
Arginine dysregulation and thrombosis may be bi-directionally linked. Intravascular 
haemolysis and subsequent NO consumption has the potential to drive a pro-coagulant state, 
as NO has properties that inhibit platelet activation, tissue factor expression and thrombin 
generation (Morris 2008). Microparticles from platelets and those produced by erythrocyte 
fragmentation during haemolysis will also activate the intrinsic phase of blood coagulation 
and trigger thrombin generation (Donadee, et al 2011, Ferru, et al 2014, Tantawy, et al 
2013). Thrombin itself increases arginase activity in human endothelial cells (Yang, et al 
2006), propagating a cycle of endothelial dysfunction. The correlation of arginase activity, 
but not concentration, to coagulation abnormalities and BNP is therefore intriguing. 
Arginase concentration and activity are closely related, but not identical, as arginase activity 
can be modulated by natural and synthetic inhibitors (Stuehr, et al 1991) or activators 
(Yang, et al 2006) that will impact its function independent of concentration.
The paradoxical association of higher 6MWD with rising TRV was unexpected. However 
thalassaemia patients have a higher than normal cardiac index, which may represent 
compensation for a more severe chronic anaemia that improves 6MWD, at least initially 
before cardiopulmonary decompensation in more severe cases. In the setting of increased 
haemolysis and anaemia, stroke volume increases leading to an increased high cardiac 
output which may increase the TRV. In addition, treatment trials for PH typically enroll 
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patients with baseline 6MWDs between 150-450 m (Galie, et al 2005). A recent study that 
reported 6MWD data in the largest cohort of patients with thalassaemia and RHC-defined 
PH revealed an atypically high baseline 6MWD for patients with PH (472±95 m) (Derchi, et 
al 2014), indicating that this may not be an ideal outcome measure in thalassaemia. In 
addition, a strong correlation of 6MWD to DLCO and FEV1/FVC % predicted may indicate 
additional pulmonary contributions to 6MWD in this cohort as confounding factors.
Patients with an elevated TRV in this thalassaemia cohort interestingly demonstrated 
evidence of left-sided cardiac dysfunction with increased left- and right-sided chamber size 
and volume. RHC data from SCD patients suggests that at least 50% of those with PH have 
evidence of elevated left- and right-sided pressures. Echocardiographic screening studies 
reveal that, while systolic dysfunction of the left ventricle and left-sided valvular heart 
disease occur in SCD, the majority of these patients have LV diastolic dysfunction, now 
termed congestive heart failure with preserved ejection fraction (Sachdev, et al 2007). MRI 
studies of thalassaemia patients demonstrate increased iron deposition within the left 
ventricle, most probably related to transfusion-associated iron overload (Wood and Noetzli 
2010). This can lead to myocardial fibrosis and decreased LV relaxation with consequent 
reduced diastolic filling. It is possible that other yet to be identified mechanisms contribute 
to this process as well, because diastolic dysfunction occurs without co-existent iron 
deposition in SCD.
Limitations
One major limitation to this and other echocardiography screening studies in thalassaemia is 
that Doppler-defined risk for PH is not confirmed by RHC, which remains the gold standard 
to diagnosis PH (Klings, et al 2014, McLaughlin, et al 2009). In clinical practice, this 
procedure is not routinely performed in patients with thalassaemia. However, there is no 
evidence to suggest that patients with thalassaemia demonstrating appropriate clinical 
indications for RHC should be excluded from general standard of care. As awareness of this 
complication increases among clinicians who appropriately refer at-risk patients to 
cardiopulmonary specialists with expertise in PH, this procedure will be recommended, 
particularly in patients with moderate elevations in their TRV (≥3.0 m/s) despite adequate 
transfusion. Small sample size is an additional limitation. Although overlap in mechanisms 
contributing to vasculopathy and PH is expected in all forms of thalassaemia, the 
pathophysiology of PH is often different in patients with TI compared to TM. Combining 
these phenotypes is not ideal, but was necessary due to limited availability of subjects and 
the orphan nature of the disease. In addition, a few TM patients had been transfused since 
infancy, suggesting that some were initially TI patients who became transfusion dependent 
over time.
Conclusions
Coagulation abnormalities, haemolysis and arginine dysregulation emerged as major 
mechanisms associated with an elevated TRV in this cohort of thalassaemia patients. An 
altered arginine metabolome has been implicated in the pathophysiology PH in a number of 
settings (Morris and Gladwin 2011). These data provide additional support for its role in 
PH-risk in thalassaemia. Nearly all human cell-types contain arginase, an intracellular 
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enzyme released into circulation upon cell damage or cell death, but the greatest source of 
arginine dysregulation in haemoglobinopathies such as SCD is erythrocyte-derived arginase-
I released during haemolysis (Morris, et al 2005a, Morris, et al 2005b). Although the 
sources and specific enzyme isoforms remain to be identified in β-thalassaemia, it is 
intriguing that arginase activity and concentration correlated so strongly to 
echocardiographic and cardiac-MRI parameters of cardiopulmonary function, a paradigm 
never previously described. It is possible that this may exist commonly in other myocardial 
disorders, particularly those associated with low GAB (Erdely, et al 2010, Sourij, et al 2011, 
Tang, et al 2009, Wang, et al 2009) and may provide a novel area to pursue therapeutically.
This study provides further evidence that arginine dysregulation may contribute to 
cardiopulmonary dysfunction in β-thalassaemia. Arginase inhibition or interventions aimed 
at restoration of GAB may hold promise for haemolytic disorders. These data may establish 
novel directions for future research in the thalassaemia syndromes and beyond.
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Figure 1. Altered arginine bioavailability in patients with β-thalassaemia and elevation of 
tricuspid regurgitant jet velocity (TRV)
A. Mean plasma arginine concentration (μM) ± standard error of the mean (SEM), B. mean 
plasma arginase concentration (ng/ml) ± SEM, C. mean plasma arginine-to-ornithine ratio 
(Arg/Orn) ± SEM and D. mean plasma global arginine bioavailability ratio (GABR, 
arginine/[ornithine+citrulline]) ± SEM in patients with β-thalassaemia with a 
tricuspidregurgitant-jet-velocity (TRV) <2.5 m/s (n=13) compared to patients with an 
elevated TRV≥2.5 m/s (n=14).
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Table I Patient Demographics and Clinical Characteristics
Total N = 27 TRV<2.5 N=13 TRV>2.5 N=14 p-value
Mean Age, years, (SD) 34.7 (11.7) 33.7 (12.6) 35.6 (11.3) 0.69
Gender, N (%)
    Male 19 (70.4%) 7 (53.9%) 12 (85.7%) 0.10
    Female 8 (29.6%) 6 (46.1%) 2 (14.3%)
Race, N (%)
    White 11 (40.7%) 4 (30.8%) 7 (50.0%) 0.45
    Black 0 (0.0%) 0 (0.0%) 0 (0.0%)
    Asian 12 (44.4%) 6 (46.2%) 6 (42.9%)
    Other 4 (14.8%) 3 (23.1%) 1 (7.1%)
Diagnosis, N (%)
    β-thalassaemia major (TM) 18 (66.7%) 11 (84.6%) 7 (50.0%)
0.10
*
        Mean transfusions per year 15.3 ± 2.4 15.3 ± 2.6 15.2 ± 2.4 0.94
        Pre-transfusion Hb 10.0 ± 0.8 9.9 ± 0.7 10.1 ± 1.1 0.79
        Transfused since infancy 11 (40.7%) 8 (61.5%) 3 (21.4%) 0.33
    β-thalassaemia intermedia (TI) 9 (33.3%) 2 (15.4%) 7 (50.0%)
        Non-transfusion 5 (18.5%) 1 (7.6%) 4 (28.6%)
>0.99
**
        < 8 transfusions/year 4 (14.8%) 1 (7.6%) 3 (21.4%)
Clinical History, N (%)
    Splenectomy 20 (74.1%) 7 (53.9%) 13 (92.9%) 0.03
    Hepatitis C 4 (14.8%) 1 (7.7%) 3 (21.4%) 0.60
    Smoking in the past year 7 (26.9%) 1 (8.3%) 6 (42.9%) 0.08
Data expressed as number (%) or mean ± SD; p-values compare data from patients with TRV<2.5 m/s vs. TRV≥2.5 m/s
TRV, tricuspid-regurgitant-jet-velocity; SD, standard deviation.
*
Compares TRV<2.5 m/s vs. TRV≥2.5 m/s in TM vs. TI
**
Compares TRV<2.5 m/s vs. TRV≥2.5 m/s between non-transfused vs. < 8 transfusion/year among TI patients
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Table II
Cardiopulmonary Characteristics According to TRV (in m/s)
Variables TRV<2.5 (n=13) TRV 2.5-2.8 (N=8) TRV≥2.9 (N=6) P-value
6MWT, NYHA class and Dyspnea
    6MWT (m) 463.2 (93.4) 504.3 (110.8) 512.3 (107.1) 0.26
    NYHA functional class 1.1 (0.3) 1.3 (0.5) 1.8 (0.4) 0.02
    Borg Dyspnea Score before walk 0.5 (1.0) 1.8 (2.0) 0.4 (0.8) 0.21
    Borg Dyspnea Score after walk 1.0 (1.0) 2.1 (1.9) 2.0 (0.9) 0.05
    Oxygen desaturation during/after 6MWT (N, %) 4 (30.8%) 4 (50.0%) 3 (50.0%) 0.44
Echo Parameters
    Local TRV (m/s) 2.1 (0.4) 2.7 (0.0) 3.6 (0.9) <0.001
    Central TRV (m/s) 2.1 (0.4) 2.6 (0.1) 3.2 (0.9) <0.001
    LVEF (%) 64.8 (3.3) 65.4 (2.5) 66.8 (2.4) 0.29
    Right atrial size (cm2) 14.2 (3.3) 16.3 (3.6) 19.2 (3.6) 0.03
    Left atrial volume (ml) 41.7 (9.7) 54.4 (12.7) 65.6 (18.5) 0.002
    LV end systolic volume (ml) 30.0 (13.5) 37.9 (13.8) 30.5 (5.8) 0.33
    LV end diastolic volume (ml) 83.4 (29.3) 109.2 (39.2) 92.5 (19.6) 0.13
    LV mass (g) 117.6 (24.7) 154.1 (43.7) 136.3 (35.1) 0.03
    LV septal wall thickness 0.8 (0.1) 0.9 (0.1) 0.9 (0.1) 0.02
    LV posterior wall thickness 0.8 (0.1) 0.9 (0.1) 0.8 (0.2) 0.07
    LV mean wall thickness 0.8 (0.1) 0.9 (0.1) 0.9 (0.1) 0.03
    Cardiac Index (l/min/m2) 2.6 (0.7) 3.7 (1.3) 3.0 (0.9) 0.04
    Arterial compliance 1.4 (0.4) 1.3 (0.5) 1.1 (0.2) 0.28
        Echo Parameters Indexed to BSA
    Right atrial size (cm2/m2) 8.8 (1.8) 9.5 (1.0) 11.3 (2.2) 0.06
    Left atrial volume (ml/m2) 25.2 (5.7) 31.6 (6.0) 38.8 (11.8) 0.004
    LV end systolic volume (ml/m2) 17.8 (6.4) 21.7 (6.8) 17.9 (3.3) 0.32
    LV end diastolic volume (ml/m2) 49.6 (13.3) 62.5 (17.8) 54.5 (12.2) 0.10
    LV mass (g/m2) 70.8 (11.8) 89.8 (24.1) 80.6 (22.8) 0.05
        MRI Parameters
    Left atrial volume (ml) 69.0 (14.6) 107.6 (34.9) 100.1 (8.3) 0.008
    LV end diastolic volume (ml) 144.5 (48.0) 200.3 (78.4) 157.1 (43.7) 0.12
    LV ejection fraction (%) 59.4 (6.3) 58.3 (3.0) 60.6 (1.1) 0.90
    LV end systolic volume (ml) 59.2 (23.5) 84.3 (35.0) 60.7 (19.4) 0.17
    LV mass (g) 72.8 (29.2) 96.0 (29.1) 87.2 (23.0) 0.11
    Right atrial volume (ml) 73.7 (17.6) 113.9 (36.7) 119.3 (17.6) 0.01
    Right ventricular end diastolic volume (ml) 138.6 (48.4) 171.6 (59.7) 161.4 (19.0) 0.16
    Right ventricular ejection fraction (%) 52.3 (5.5) 53.1 (6.2) 44.9 (10.6) 0.47
    Right ventricular end systolic volume (ml) 67.2 (27.4) 80.1 (28.9) 87.5 (18.5) 0.17
        Pulmonary Function













Morris et al. Page 19
Variables TRV<2.5 (n=13) TRV 2.5-2.8 (N=8) TRV≥2.9 (N=6) P-value
    Oxygen saturation on room air before walk (%) 98.0 (1.6) 96.6 (2.0) 97.2 (2.5) 0.13
    Oxygen saturation on room air after walk (%) 98.2 (1.6) 95.5 (1.5) 98.2 (2.3) 0.09
    DLCO 13.0 (5.8) 13.9 (11.0) 15.8 (7.2) 0.58
    DLCO % predicted 65.8 (15.1) 68.9 (19.2) 71.8 (16.8) 0.51
    DLCO adjusted for Hb 17.4 (5.4) 20.7 (12.4) 21.3 (6.8) 0.29
    FEV1 % predicted 82.5 (8.7) 87.4 (13.9) 80.2 (12.5) 0.69
    FEV/FVC % predicted 98.1 (6.8) 100.3 (6.9) 93.8 (9.3) 0.82
    FEF (25-75) % predicted 84.6 (19.2) 74.0 (31.2) 121.0 (41.4) 0.35
    FVLC % predicted 85.8 (10.8) 91.3 (16.0) 83.7 (15.0) 0.67
    Total lung capacity % predicted 86.6 (13.9) 88.5 (15.6) 90.5 (6.4) 0.74
Data expressed as number (%) or mean ± SD; p-values compare data from patients with TRV<2.5 m/s vs. TRV≥2.5 m/s
Abbreviations: BSA, body surface area index; CT, computerized tomography; DLCO, diffusing capacity for carbon monoxide; Echo, Doppler-
echocardiography; FEF, forced expiratory flow; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; H, haemoglobin; LV, left 
ventricular; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imagining; NYHA, New York Heart Association; 6MWT, 6-minute 
walk test; TRV, tricuspid regurgitant jet velocity
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Table III
Laboratory Variables According to TRV
Variables TRV<2.5 (N=13) TRV≥2.5 (N=14) p-value
Clinical Laboratory Analyses
    WBC (109/l) 10.8 (4.7) 13.8 (4.6) 0.11
    Platelet Count (109/l) 478.3 (280.6) 581.2 (257.1) 0.34
    Haemoglobin (g/l) 108 (12) 100 (22) 0.25
    Haematocrit (%) 32.2 (2.9) 31.3 (6.0) 0.62
    Ferritin (μg/l) 3028 (3735) 1636 (1552) 0.51
    Bilirubin (μmol/l) 32.5 (18.8) 42.8 (23.9) 0.30
    ALT (u/l) 34.3 (24.7) 34.0 (30.5) 0.82
    AST (u/l) 33.8 (20.7) 51.4 (32.7) 0.20
    Creatinine (μmol/l) 61.9 (17.7) 61.9 (26.5) 0.92
    BNP (pg/ml) 23.6 (28.4) 43.5 (51.6) 0.24
Coagulation
    PAI-1 Activity (iu/ml) 13.8 (12.9) 8.7 (4.3) 0.32
    PF12 Mono (pmol/l) 124.4 (55.1) 696.9 (1311) 0.02
    TAT Complex (ng/ml) 3.3 (2.0) 70.1 (174.0) 0.04
    TF (pg/ml) 279.1 (84.9) 296.2 (112.6) 0.71
Haemolysis/Arginine - Nitric Oxide Pathway
    LDH (iu/l) 165.3 (42.5) 236.2 (87.0) 0.03
    Arginine (Plasma; μM) 88.2 (30.1) 46.8 (25.8) 0.001
    Arginine (erythrocyte; μM) 4.5 (3.0) 4.3 (3.0) 0.78
    Arginase concentration (ng/ml) 5.7 (7.0) 78.7 (108.0) 0.003
    Arginase activity (u/l) 2.5 (2.6) 7.8 (7.1) 0.05
    Plasma Arg/Orn 3.4 (2.2) 1.6 (1.1) 0.01
    Plasma Arg/(Orn+Citrulline) 2.5 (2.4) 1.1 (0.7) 0.04
    Serum NOx concentration (μM) 31.4 (9.4) 40.9 (17.1) 0.10
    VEGF (pg/ml) 842.9 (833.0) 1013 (819.1) 0.23
    GSH (RBC; μM) 1807 (860.5) 1501 (799.7) 0.61
    Cell Free Haemoglobin (μg/ml) 155.0 (90.8) 182.6 (115.9) 0.58
Data expressed as mean ± standard deviation
Abbreviations: ALT, alanine transaminase; Arg, arginine; AST, aspartate transaminase; BNP, brain natriuretic peptide; GSH, glutathione; LDH, 
lactate dehydrogenase; NOx, nitric oxide metabolites; Orn, ornithine; PAI1, plasminogen activator inhibitor-1; PF1.2 Mono, monoclonal 
prothrombin fragment 1.2 ; RBC, red blood cell; TAT, thrombin-anti-thrombin ; TF, tissue factor; VEGF, vascular endothelial growth factor; 
WBC, white blood cell count.
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Table IV
Associations with Arginase Concentration as Measured by Pearson Correlation Coefficient
Variable r No. With Data p-value
Echo Parameters
    Local TRV (m/s) 0.12 26 0.55
    Central TRV (m/s) 0.06 26 0.77
    Left atrial volume (ml) 0.48 26 0.01
    LV end systolic volume (ml) 0.47 26 0.02
    LV end diastolic volume (ml) 0.57 26 0.002
    LV mass (g) 0.49 26 0.01
    LV mean wall thickness 0.36 26 0.07
    Cardiac Index (l/min/m2) 0.75 26 <.0001
Echo Parameters Indexed to BSA
    Right atrial size (cm2/m2) −0.03 25 0.87
    Left atrial volume (ml/m2) 0.46 26 0.02
    LV end systolic volume (ml/m2) 0.56 26 0.003
    LV end diastolic volume (ml/m2) 0.67 26 0.0002
    LV mass (g/m2) 0.48 26 0.01
MRI Parameters
    Left atrial volume (ml) 0.79 14 0.001
    LV end systolic volume (ml) 0.53 22 0.01
    LV end systolic volume (ml) 0.54 22 0.01
    LV mass (g) 0.49 21 0.02
    Right atrial volume (ml) 0.79 13 0.001
    RV end diastolic volume (ml) 0.32 22 0.14
Clinical Lab Analyses
    WBC (109/l) 0.43 25 0.03
    Platelet Count (109/l) 0.32 25 0.12
    Haemoglobin (g/l) −0.46 26 0.02
    Bilirubin (μmol/l) 0.50 23 0.02
    ALT (u/l) 0.19 26 0.36
    AST (u/l) 0.23 16 0.39
    Creatinine (μmol/l) −0.47 26 0.02
Haemolysis
    LDH (iu/l) 0.63 24 0.001
    Arginine (plasma, μM) −0.67 26 0.0002
    Arginine (erythrocyte, μM) 0.09 25 0.68
    Arginine/Ornithine (plasma) −0.51 26 0.01
    Arginine/(Ornithine+Citrulline) -0.39 26 0.05
    Serum NOx concentration (μM) 0.17 25 0.41
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Variable r No. With Data p-value
    Cell Free Haemoglobin (μg/ml) −0.14 26 0.50
Abbreviations: ALT, alanine transaminase; Arg, arginine; AST, aspartate transaminase; LDH, lactate dehydrogenase; LV, left ventricular; NOx, 
nitric oxide metabolites; Orn, ornithine; RV, right ventricular; TRV, tricuspid regurgitant jet velocity; WBC, white blood cell count. alanine 
aminotransferase (ALT); aspartate aminotransferase (AST); lactate dehydrogenase (LDH); left
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